Michael Brian Bell Sells 2,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CFO Michael Brian Bell sold 2,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the transaction, the chief financial officer owned 47,509 shares in the company, valued at approximately $6,110,607.58. This trade represents a 4.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Brian Bell also recently made the following trade(s):

• On Monday, March 16th, Michael Brian Bell sold 3,000 shares of Guardant Health stock. The stock was sold at an average price of $87.04, for a total value of $261,120.00.

Guardant Health Price Performance

Shares of GH stock opened at $130.12 on Wednesday. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $134.28. The stock’s fifty day moving average price is $101.04 and its 200 day moving average price is $101.54. The company has a market cap of $17.25 billion, a price-to-earnings ratio of -38.38 and a beta of 1.61.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GH shares. Canaccord Genuity Group boosted their price target on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, February 20th. The Goldman Sachs Group started coverage on Guardant Health in a research note on Friday. They set a “buy” rating and a $165.00 price target on the stock. Wolfe Research started coverage on Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target on the stock. Stifel Nicolaus boosted their price target on Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Finally, Evercore upgraded Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price target on the stock in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average target price of $139.80.

Hedge Funds Weigh In On Guardant Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC lifted its holdings in shares of Guardant Health by 87.5% in the 1st quarter. Perceptive Advisors LLC now owns 300,000 shares of the company’s stock valued at $27,711,000 after buying an additional 140,000 shares during the period. BankChampaign National Association acquired a new position in shares of Guardant Health in the 1st quarter valued at about $809,000. Western Wealth Management LLC acquired a new position in shares of Guardant Health in the 1st quarter valued at about $125,000. Hamilton Wealth LLC lifted its holdings in shares of Guardant Health by 103.0% in the 1st quarter. Hamilton Wealth LLC now owns 76,700 shares of the company’s stock valued at $7,085,000 after buying an additional 38,916 shares during the period. Finally, Edgestream Partners L.P. lifted its holdings in shares of Guardant Health by 321.6% in the 1st quarter. Edgestream Partners L.P. now owns 32,257 shares of the company’s stock valued at $2,980,000 after buying an additional 24,606 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.